NCI seeks suramin research partner
National Cancer Institute announces opportunity for a Cooperative Research and Development Agreement (CRADA) for clinical development of its anti-cancer compound suramin. NCI says the drug appears effective in treating several types of cancers in pre-clinical studies. A study reported in the Jan. 1 Journal of the National Cancer Institute by University of Maryland researchers states that prolonged administration of suramin over at least three months "was associated with major antitumor activity" in patients with prostate cancer. Of 26 evaluable patients, 14 have shown a 50% or greater decrease. Information may be obtained from Dale Shoemaker, Executive Secretary, CRADA Selection Committee, 301/496-7912.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth